Angiotensin coverting enzyme (ACE) and HydroxyMethylGlutaryl-CoA (HMG-CoA) reductase inhibitors in the forefront of pharmacology of endothelium

Pharmacological Reports

Volumn 57, Issue SUPPL., 2005, Pages 86-96

  Chłopicki, Stefan ^a   Gryglewski, Ryszard J ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

ACE; ACE I; Atherothrombosis; Endothelium; HMG CoA reductase; Pleiotropic drug action; Statins

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRADYKININ; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; CARVEDILOL; CERIVASTATIN; COMPACTIN; CYTOKINE; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN RECEPTOR ANTAGONIST; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NEBIVOLOL; NITRIC OXIDE; PERINDOPRIL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PROSTACYCLIN; QUINAPRIL; RAMIPRIL; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SIMVASTATIN; UNINDEXED DRUG; VASOPEPTIDASE INHIBITOR; XANTHINE OXIDASE INHIBITOR;

ANTIHYPERTENSIVE ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ARTERIAL PRESSURE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; ENDOTHELIAL DYSFUNCTION; ENZYME BLOOD LEVEL; ENZYME INHIBITION; ENZYME LOCALIZATION; FIBRINOLYSIS; HEART PROTECTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; NONHUMAN; PATHOGENESIS; PHENOTYPE; PROGNOSIS; PROTEIN EXPRESSION; REVIEW; RISK ASSESSMENT; RISK FACTOR; THROMBUS; VASCULAR DISEASE; VASCULAR ENDOTHELIUM; VASODILATATION; ANIMAL; DRUG EFFECT; PATHOPHYSIOLOGY; THROMBOSIS;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ATHEROSCLEROSIS; ENDOTHELIUM, VASCULAR; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; THROMBOSIS; VASCULAR DISEASES;

EID: 33645692159     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: None     Document Type: Review

References (120)

1. Blake GJ, Ridker PM: Novel clinical markers of vascular wall inflammation. Circ Res, 2001, 89, 763-771.
2. Blankenberg S, Rupprecht HJ, Bickel C, Peetz D, Hafner G, Tiret L, Meyer J: Circulating cell adhesion molecules and death in patients with coronary artery disease. Circulation, 2001, 104, 1336-1342.
3. Bonetti PO, Lerman LO, Lerman A: Endothelial dysfunction: a marker of atherosclerotic risk. Arterioscler Thromb Vasc Biol, 2003, 23, 168-175.
4. Bourcier T, Libby P: HMG CoA reductase inhibitors reduce plasminogen activator inhibitor-1 expression by human vascular smooth muscle and endothelial cells. Arterioscler Thromb Vasc Biol, 2000, 20, 556-562.
5. Brevetti G, Silvestro A, Schiano V, Chiariello M: Endothelial dysfunction and cardiovascular risk prediction in peripheral arterial disease: additive value of flow-mediated dilation to ankle-brachial pressure index. Circulation, 2003, 108, 2093-2098.
6. Campbell DJ, Krum H, Esler MD: Losartan increases bradykinin levels in hypertensive humans. Circulation, 2005, 111, 315-320.
7. Celermajer DS, Sorensen KE, Bull C, Robinson J, Deanfield JE: Endothelium-dependent dilation in the systemic arteries of asymptomatic subjects relates to coronary risk factors and their interaction. J Am Coll Cardiol, 1994, 24, 1468-1474.
8. Chan AW, Bhatt DL, Chew DP, Quinn MJ, Moliterno DJ, Topol EJ, Ellis SG: Early and sustained survival benefit associated with statin therapy at the time of percutaneous coronary intervention. Circulation, 2002, 105, 691-696.
9. Chew DP, Bhatt DL, Robbins MA, Penn MS, Schneider JP, Lauer MS, Topol EJ et al.: Incremental prognostic value of elevated baseline C-reactive protein among established markers of risk in percutaneous coronary intervention. Circulation, 2001, 104, 992-997.
10. Chłopicki S, Kozlovski VI, Gryglewski RJ: No-dependent vasodilation induced by nebivolol in coronary circulation is not mediated by beta-adrenoceptors or by 5 HT1A-receptors. J Physiol Pharmacol, 2002, 53, 615-624.
11. Collins RG, Velji R, Guevara NV, Hicks MJ, Chan L, Beaudet AL: P-Selectin or intercellular adhesion molecule (ICAM)-1 deficiency substantially protects against atherosclerosis in apolipoprotein E- deficient mice. J Exp Med, 2000, 191, 189-194.
12. d'Uscio LV, Barton M, Shaw S, Luscher TF: Chronic ET(A) receptor blockade prevents endothelial dysfunction of small arteries in apolipoprotein E-deficient mice. Cardiovasc Res, 2002, 53, 487-495.
13. Dagenais GR, Yusuf S, Bourassa MG, Yi Q, Bosch J, Lonn EM, Kouz S et al.: Effects of ramipril on coronary events in high-risk persons: results of the Heart Outcomes Prevention Evaluation Study. Circulation, 2001, 104, 522-526.
14. Davis SF, Yeung AC, Meredith IT, Charbonneau F, Ganz P, Selwyn AP, Anderson TJ: Early endothelial dysfunction predicts the development of transplant coronary artery disease at 1 year posttransplant. Circulation, 1996, 93, 457-462.
15. Diep QN, Amiri F, Touyz RM, Cohn JS, Endemann D, Neves MF, Schiffrin EL: PPARalpha activator effects on Ang II-induced vascular oxidative stress and inflammation. Hypertension, 2002, 40, 866-871.
16. Drexler H: Nitric oxide and coronary endothelial dysfunction in humans. Cardiovasc Res, 1999, 43, 572-579.
17. Dupin JP, Gryglewski RJ, Gravier D, Hou G, Casadebaig F, Swies J, Chłopicki S: Synthesis and thrombolytic activity of new thienopyrimidinone derivatives. J Physiol Pharmacol, 2002, 53, 625-634.
18. Dzau VJ: Tissue renin-angiotensin system in myocardial hypertrophy and failure. Arch Intern Med, 1993, 153, 937-942.
19. Effect of nifedipine and cerivastatin on coronary endothelial function in patients with coronary artery disease: the ENCORE I Study (Evaluation of Nifedipine and Cerivastatin On Recovery of coronary Endothelial function). Circulation, 2003, 107, 422-428.
20. Endo A, Kuroda M, Tsujita Y: ML-236A, ML-236B, and ML-236C, new inhibitors of cholesterogenesis produced by Penicillium citrinium. J Antibiot (Tokyo), 1976, 29, 1346-1348.
21. Essig M, Nguyen G, Prie D, Escoubet B, Sraer JD, Friedlander G: 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors increase fibrinolytic activity in rat aortic endothelial cells. Role of geranylgeranylation and Rho proteins. Circ Res, 1998, 83, 683-690.
22. Faggiotto A, Paoletti R: State-of-the-Art lecture. Statins and blockers of the renin-angiotensin system: vascular protection beyond their primary mode of action. Hypertension, 1999, 34, 987-996.
23. Fichtlscherer S, Rosenberger G, Walter DH, Breuer S, Dimmeler S, Zeiher AM: Elevated C-reactive protein levels and impaired endothelial vasoreactivity in patients with coronary artery disease. Circulation, 2000, 102, 1000-1006.
24. Fox R: American Heart Association 2001 scientific sessions: late-breaking science-statins: the new aspirin? Circulation, 2001, 104, E9051-E9052.
25. Fukuo K, Yang J, Yasuda O, Mogi M, Suhara T, Sato N, Suzuki T et al.: Nifedipine indirectly upregulates superoxide dismutase expression in endothelial cells via vascular smooth muscle cell-dependent pathways. Circulation, 2002, 106, 356-361.
26. Fuller JA: Combine EUROPA and HOPE. Lancet, 2003, 362, 1937.
27. Ghiadoni L, Magagna A, Versari D, Kardasz I, Huang Y, Taddei S, Salvetti A: Different effect of antihypertensive drugs on conduit artery endothelial function. Hypertension, 2003, 41, 1281-1286.
28. Gokce N, Keaney JF Jr, Hunter LM, Watkins MT, Menzoian JO, Vita JA: Risk stratification for postoperative cardiovascular events via noninvasive assessment of endothelial function: a prospective study. Circulation, 2002, 105, 1567-1572.
29. Gosling J, Slaymaker S, Gu L, Tseng S, Zlot CH, Young SG, Rollins BJ et al.: MCP-1 deficiency reduces susceptibility to atherosclerosis in mice that overexpress human apolipoprotein B. J Clin Invest, 1999, 103, 773-778.
30. Griendling KK, Sorescu D, Ushio-Fukai M: NAD(P)H oxidase: role in cardiovascular biology and disease. Circ Res, 2000, 86, 494-501.
31. Gryglewski RJ, Chłopicki S, Swies J: In vivo endothelial interaction between ACE and COX inhibitors. Prostaglandins Leukot Essent Fatty Acids, 2005, 72, 129-131.
32. Gryglewski RJ, Dupin JP, Uracz W, Swies J, Madej J, Hou G, Gravier D et al.: Thrombolysis by thienopyridines and their congeners. J Physiol Pharmacol, 2000, 51, 683-693.
33. Gryglewski RJ, Korbut R, Swies J, Kostka TE, Bieron K, Robak J: Thrombolytic action of ticlopidine: possible mechanisms. Eur J Pharmacol, 1996, 308, 61-67.
34. Gryglewski RJ, Swies J, Uracz W, Chłopicki S, Marcinkiewicz E: Mechanisms of angiotensin-converting enzyme inhibitor induced thrombolysis in Wistar rats. Thromb Res, 2003, 110, 323-329.
35. Gryglewski RJ, Uracz W, Chłopicki S, Marcinkiewicz E: Bradykinin as a major endogenous regulator of endothelial function. Pediatr Pathol Mol Med, 2002, 21, 279-290.
36. Gryglewski RJ, Uracz W, Swies J, Chłopicki S, Marcinkiewicz E, Lomnicka M, Madej J: Comparison of endothelial pleiotropic actions of angiotensin converting enzyme inhibitors and statins. Ann NY Acad Sci, 2001, 947, 229-245.
37. Guthikonda S, Sinkey C, Barenz T, Haynes WG: Xanthine oxidase inhibition reverses endothelial dysfunction in heavy smokers. Circulation, 2003, 107, 416-421.
38. Halcox JP, Schenke WH, Zalos G, Mincemoyer R, Prasad A, Waclawiw MA, Nour KR et al.: Prognostic value of coronary vascular endothelial dysfunction. Circulation, 2002, 106, 653-658.
39. Hansson GK: Immune mechanisms in atherosclerosis. Arterioscler Thromb Vasc Biol, 2001, 21, 1876-1890.
40. Heitzer T, Schlinzig T, Krohn K, Meinertz T, Munzel T: Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. Circulation, 2001, 104, 2673-2678.
41. Hernandez-Perera O, Perez-Sala D, Soria E, Lamas S: Involvement of Rho GTPases in the transcriptional inhibition of preproendothelin-1 gene expression by simvastatin in vascular endothelial cells. Circ Res, 2000, 87, 616-622.
42. Heusch G, Rose J, Ehring T: Cardioprotection by ACE inhibitors in myocardial ischemia/reperfusion. The importance of bradykinin. Drugs, 1997, 54, Suppl 5, 31-41.
43. Inoue I, Goto S, Mizotani K, Awata T, Mastunaga T, Kawai S, Nakajima T et al.: Lipophilic HMG-CoA reductase inhibitor has an anti-inflammatory effect: reduction of MRNA levels for interleukin-1beta, interleukin-6, cyclooxygenase-2, and p22phox by regulation of peroxisome proliferator-activated receptor alpha (PPARalpha) in primary endothelial cells. Life Sci, 2000, 67, 863-876.
44. Jakubowski A, Chłopicki S, Olszanecki R, Jawien J, Lomnicka M, Dupin JP, Gryglewski RJ: Endothelial action of thienopyridines and thienopyrimidinones in the isolated guinea pig heart. Prostaglandins Leukot Essent Fatty Acids, 2005, 72, 139-145.
45. Juhan-Vague I, Alessi MC, Joly P, Thirion X, Vague P, Declerck PJ, Serradimigni A et al.: Plasma plasminogen activator inhibitor-1 in angina pectoris. Influence of plasma insulin and acute-phase response. Arteriosclerosis, 1989, 9, 362-367.
46. Kalinowski L, Dobrucki LW, Szczepanska-Konkel M, Jankowski M, Martyniec L, Angielski S, Malinski T: Third-generation beta-blockers stimulate nitric oxide release from endothelial cells through ATP efflux: a novel mechanism for antihypertensive action. Circulation, 2003, 107, 2747-2752.
47. Keaney JF Jr: Atherosclerosis: from lesion formation to plaque activation and endothelial dysfunction. Mol Aspects Med, 2000, 21, 99-166.
48. Kyrle PA, Minar E, Brenner B, Eichler HG, Heistinger M, Marosi L, Lechner K: Thromboxane A2 and prostacyclin generation in the microvasculature of patients with atherosclerosis-effect of low-dose aspirin. Thromb Haemost, 1989, 61, 374-377.
49. Laufs U, La F, V, Plutzky J, Liao JK: Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation, 1998, 97, 1129-1135.
50. Lefer AM, Scalia R, Lefer DJ: Vascular effects of HMG CoA-reductase inhibitors (statins) unrelated to cholesterol lowering: new concepts for cardiovascular disease. Cardiovasc Res, 2001, 49, 281-287.
51. Lerman A, Holmes DR Jr, Bell MR, Garratt KN, Nishimura RA, Burnett JC Jr: Endothelin in coronary endothelial dysfunction and early atherosclerosis in humans. Circulation, 1995, 92, 2426-2431.
52. Levine GN, Keaney JF Jr, Vita JA: Cholesterol reduction in cardiovascular disease. Clinical benefits and possible mechanisms. N Engl J Med, 1995, 332, 512-521.
53. Ley K, Huo Y: VCAM-1 is critical in atherosclerosis. J Clin Invest, 2001, 107, 1209-1210.
54. Libby P: Current concepts of the pathogenesis of the acute coronary syndromes. Circulation, 2001, 104, 365-372.
55. Libby P, Aikawa M, Schonbeck U: Cholesterol and atherosclerosis. Biochim Biophys Acta, 2000, 1529, 299-309.
56. Libby P, Ridker PM, Maseri A: Inflammation and atherosclerosis. Circulation, 2002, 105, 1135-1143.
57. Libby P, Simon DI: Inflammation and thrombosis: the clot thickens. Circulation, 2001, 103, 1718-1720.
58. Lorkowska B, Chłopicki S: Statins as coronary vasodilators in isolated bovine coronary arteries-involvement of PGI2 and NO. Prostaglandins Leukot Essent Fatty Acids, 2005, 72, 133-138.
59. 2+]i in cultured endothelial cells. Pol J Pharmacol, 2004, 56, 313-318.
60. Lusis AJ: Atherosclerosis. Nature, 2000, 407, 233-241.
61. Marin-Castano ME, Schanstra JP, Neau E, Praddaude F, Pecher C, Ader JL, Girolami JP et al.: Induction of functional bradykinin b(1)-receptors in normotensive rats and mice under chronic Angiotensin-converting enzyme inhibitor treatment. Circulation, 2002, 105, 627-632.
62. Maron DJ, Fazio S, Linton MF: Current perspectives on statins. Circulation, 2000, 101, 207-213.
63. Modena MG, Bonetti L, Coppi F, Bursi F, Rossi R: Prognostic role of reversible endothelial dysfunction in hypertensive postmenopausal women. J Am Coll Cardiol, 2002, 40, 505-510.
64. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet, 2002, 360, 7-22.
65. Mueck AO, Seeger H, Wallwiener D: Further evidence for direct vascular actions of statins: effect on endothelial nitric oxide synthase and adhesion molecules. Exp Clin Endocrinol Diabetes, 2001, 109, 181-183.
66. Muntwyler J, Gutzwiller F: Statins and mortality. Eur Heart J, 2002, 23, 183-184.
67. Munzel T, Keaney JF Jr: Are ACE inhibitors a "magic bullet" against oxidative stress? Circulation, 2001, 104, 1571-1574.
68. Newby DE, McLeod AL, Uren NG, Flint L, Ludlam CA, Webb DJ, Fox KA et al.: Impaired coronary tissue plasminogen activator release is associated with coronary atherosclerosis and cigarette smoking: direct link between endothelial dysfunction and atherothrombosis. Circulation, 2001, 103, 1936-1941.
69. Nickenig G, Harrison DG: The AT(1)-type angiotensin receptor in oxidative stress and atherogenesis: part I: oxidative stress and atherogenesis. Circulation, 2002, 105, 393-396.
70. Pahor M, Franse LV, Deitcher SR, Cushman WC, Johnson KC, Shorr RI, Kottke-Marchant K et al.: Fosinopril versus amlodipine comparative treatments study: a randomized trial to assess effects on plasminogen activator inhibitor-1. Circulation, 2002, 105, 457-461.
71. Perticone F, Ceravolo R, Pujia A, Ventura G, Iacopino S, Scozzafava A, Ferraro A et al.: Prognostic significance of endothelial dysfunction in hypertensive patients. Circulation, 2001, 104, 191-196.
72. Plutzky J, Ridker PM: Statins for stroke: the second story? Circulation, 2001, 103, 348-350.
73. Prasad A, Zhu J, Halcox JP, Waclawiw MA, Epstein SE, Quyyumi AA: Predisposition to atherosclerosis by infections: role of endothelial dysfunction. Circulation, 2002, 106, 184-190.
74. Quyyumi AA: Endothelial function in health and disease: new insights into the genesis of cardiovascular disease. Am J Med, 1998, 105, 32S-39S.
75. Raitakari OT, Celermajer DS: Flow-mediated dilatation. Br J Clin Pharmacol, 2000, 50, 397-404.
76. Raitakari OT, Celermajer DS: Testing for endothelial dysfunction. Ann Med, 2000, 32, 293-304.
77. Remme WJ: Bradykinin-mediated cardiovascular protective actions of ACE inhibitors. A new dimension in antiischemic therapy? Drugs, 1997, 54, Suppl 5, 59-70.
78. Rogerson FM, Chai SY, Schlawe I, Murray WK, Marley PD, Mendelsohn FA: Presence of angiotensin converting enzyme in the adventitia of large blood vessels. J Hypertens, 1992, 10, 615-620.
79. Ross R: Atherosclerosis is an inflammatory disease. Am Heart J, 1999, 138, S419-S420.
80. Ross R: Atherosclerosis-an inflammatory disease. N Engl J Med, 1999, 340, 115-126.
81. Ross R, Glomset J, Harker L: Response to injury and atherogenesis. Am J Pathol, 1977, 86, 675-684.
82. Ruggeri ZM: Platelets in atherothrombosis. Nat Med, 2002, 8, 1227-1234.
83. Schachinger V, Britten MB, Zeiher AM: Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation, 2000, 101, 1899-1906.
84. Schafer A, Fraccarollo D, Hildemann SK, Tas P, Ertl G, Bauersachs J: Addition of the selective aldosterone receptor antagonist eplerenone to ACE inhibition in heart failure: effect on endothelial dysfunction. Cardiovasc Res, 2003, 58, 655-662.
85. Schafer S, Steioff K, Linz W, Bleich M, Busch AE, Lohn M: Chronic vasopeptidase inhibition normalizes diabetic endothelial dysfunction. Eur J Pharmacol, 2004, 484, 361-362.
86. Schindler TH, Hornig B, Buser PT, Olschewski M, Magosaki N, Pfisterer M, Nitzsche EU et al.: Prognostic value of abnormal vasoreactivity of epicardial coronary arteries to sympathetic stimulation in patients with normal coronary angiograms. Arterioscler Thromb Vasc Biol, 2003, 23, 495-501.
87. Schumacher A, Seljeflot I, Sommervoll L, Christensen B, Otterstad JE, Arnesen H: Increased levels of endothelial haemostatic markers in patients with coronary heart disease. Thromb Res, 2002, 105, 25-31.
88. Sinzinger H, Kaliman J, Silberbauer K, Oppolzer R: Diminished prostacyclin formation in forearm venous tissue of patients with peripheral occlusive arteriopathy. Exp Pathol (Jena), 1980, 18, 254-255.
89. Sleight P: The HOPE Study (Heart Outcomes Prevention Evaluation). J Renin Angiotensin Aldosterone Syst, 2000, 1, 18-20.
90. Sood HS, Hunt MJ, Tyagi SC: Peroxisome proliferator ameliorates endothelial dysfunction in a murine model of hyperhomocysteinemia. Am J Physiol Lung Cell Mol Physiol, 2003, 284, L333-L341.
91. Sun Y, Zhang JQ, Zhang J, Ramires FJ: Angiotensin II, transforming growth factor-beta1 and repair in the infarcted heart. J Mol Cell Cardiol, 1998, 30, 1559-1569.
92. Supniewski J, Chrusciel T, Czekaj S, Ostachowska T: The effect of 2-methyl-2-butene-carboxylic acid on experimental atherosclerosis in the pigeon (Polish). Dessertationes Pharmaceuticae, 1959, XI, 201-216.
93. Supniewski J, Chrusciel T, Czekaj S, Ostachowska T: Investigation on Experimental Atherosclerosis. The effect of 2-methyl-2-butene-carboxylic acid on experimental atherosclerosis in the pigeon. Bulletin de L'Academie Polonasie des Sciences, 1959, VII, 199-201.
94. Suwaidi JA, Hamasaki S, Higano ST, Nishimura RA, Holmes DR Jr, Lerman A: Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation, 2000, 101, 948-954.
95. Takemoto M, Liao JK: Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. Arterioscler Thromb Vasc Biol, 2001, 21, 1712-1719.
96. Targonski PV, Bonetti PO, Pumper GM, Higano ST, Holmes DR Jr, Lerman A: Coronary endothelial dysfunction is associated with an increased risk of cerebrovascular events. Circulation, 2003, 107, 2805-2809.
97. Tzemos N, Lim PO, MacDonald TM: Nebivolol reverses endothelial dysfunction in essential hypertension: a randomized, double-blind, crossover study. Circulation, 2001, 104, 511-514.
98. Udvardy M, Torok I, Rak K: Plasma thromboxane and prostacyclin metabolite ratio in atherosclerosis and diabetes mellitus. Thromb Res, 1987, 47, 479-484.
99. Undas A, Brummel-Ziedins KE, Mann KG: Statins and blood coagulation. Arterioscler Thromb Vasc Biol, 2005, 25, 287-294.
100. Vane JR: The Croonian Lecture, 1993. The endothelium: maestro of blood circulation. Phil Trans R Soc Lond B, 1994, 343, 225-246.
101. Verma S, Anderson TJ: Fundamentals of endothelial function for the clinical cardiologist. Circulation, 2002, 105, 546-549.
102. Vita JA, Keaney JF Jr.: Endothelial function: a barometer for cardiovascular risk? Circulation, 2002, 106, 640-642.
103. Vita JA, Loscalzo J: Shouldering the risk factor burden: infection, atherosclerosis, and the vascular endothelium. Circulation, 2002, 106, 164-166.
104. Vita JA, Treasure CB, Nabel EG, McLenachan JM, Fish RD, Yeung AC, Vekshtein VI et al.: Coronary vasomotor response to acetylcholine relates to risk factors for coronary artery disease. Circulation, 1990, 81, 491-497.
105. Wagner AH, Gebauer M, Guldenzoph B, Hecker M: 3-hydroxy-3-methylglutaryl coenzyme A reductase-independent inhibition of CD40 expression by atorvastatin in human endothelial cells. Arterioscler Thromb Vasc Biol, 2002, 22, 1784-1789.
106. Wagner AH, Kohler T, Ruckschloss U, Just I, Hecker M: Improvement of nitric oxide-dependent vasodilatation by HMG-CoA reductase inhibitors through attenuation of endothelial superoxide anion formation. Arterioscler Thromb Vasc Biol, 2000, 20, 61-69.
107. Wagner AH, Schwabe O, Hecker M: Atorvastatin inhibition of cytokine-inducible nitric oxide synthase expression in native endothelial cells in situ. Br J Pharmacol, 2002, 136, 143-149.
108. Wald NJ, Law MR: A strategy to reduce cardiovascular disease by more than 80%. BMJ, 2003, 326, 1419.
109. Wassmann S, Laufs U, Baumer AT, Muller K, Ahlbory K, Linz W, Itter G et al.: HMG-CoA reductase inhibitors improve endothelial dysfunction in normocholesterolemic hypertension via reduced production of reactive oxygen species. Hypertension, 2001, 37, 1450-1457.
110. Wassmann S, Laufs U, Baumer AT, Muller K, Konkol C, Sauer H, Bohm M et al.: Inhibition of geranylgeranylation reduces angiotensin II-mediated free radical production in vascular smooth muscle cells: involvement of angiotensin AT1 receptor expression and Rac1 GTPase. Mol Pharmacol, 2001, 59, 646-654.
111. Weber C, Erl W, Weber KS, Weber PC: HMG-CoA reductase inhibitors decrease CD11b expression and CD11b-dependent adhesion of monocytes to endothelium and reduce increased adhesiveness of monocytes isolated from patients with hypercholesterolemia. J Am Coll Cardiol, 1997, 30, 1212-1217.
112. Weber KT, Sun Y: Recruitable ACE and tissue repair in the infarcted hear. J Renin Angiotensin Aldosterone Syst, 2000, 1, 295-303.
113. Weitz-Schmidt G: Statins as anti-inflammatory agents. Trends Pharmacol Sci, 2002, 23, 482-486.
114. Werns SW, Walton JA, Hsia HH, Nabel EG, Sanz ML, Pitt B: Evidence of endothelial dysfunction in angiographically normal coronary arteries of patients with coronary artery disease. Circulation, 1989, 79, 287-291.
115. Westrick RJ, Bodary PF, Xu Z, Shen YC, Broze GJ, Eitzman DT: Deficiency of tissue factor pathway inhibitor promotes atherosclerosis and thrombosis in mice. Circulation, 2001, 103, 3044-3046.
116. Wilson SH, Herrmann J, Lerman LO, Holmes DR Jr, Napoli C, Ritman EL, Lerman A: Simvastatin preserves the structure of coronary adventitial vasa vasorum in experimental hypercholesterolemia independent of lipid lowering. Circulation, 2002, 105, 415-418.
117. Wolfrum S, Jensen KS, Liao JK: Endothelium-dependent effects of statins. Arterioscler Thromb Vasc Biol, 2003, 23, 729-736.
118. Zeiher AM, Drexler H, Wollschlager H, Just H: Modulation of coronary vasomotor tone in humans. Progressive endothelial dysfunction with different early stages of coronary atherosclerosis. Circulation, 1991, 83, 391-401.
119. Zhu P, Zaugg CE, Hornstein PS, Allegrini PR, Buser PT: Bradykinin-dependent cardioprotective effects of losartan against ischemia and reperfusion in rat hearts. J Cardiovasc Pharmacol, 1999, 33, 785-790.
120. Zhuo JL, Froomes P, Casley D, Liu JJ, Murone C, Chai SY, Buxton B et al.: Perindopril chronically inhibits angiotensin-converting enzyme in both the endothelium and adventitia of the internal mammary artery in patients with ischemic heart disease. Circulation, 1997, 96, 174-182.